A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial

Huei Ting Tsai, Stanley N. Caroff, Del D. Miller, Joseph Patrick McEvoy, Jeffrey A. Lieberman, Kari E. North, T. Scott Stroup, Patrick F. Sullivan

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.

Original languageEnglish (US)
Pages (from-to)336-340
Number of pages5
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Volume153
Issue number1
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Clinical Trials
Genes
Movement Disorders
Haplotypes
Single Nucleotide Polymorphism
Glutamic Acid
Dopamine
Serotonin
Extremities
Genotype
Enzymes
Pharmaceutical Preparations
Tardive Dyskinesia
Abnormal Involuntary Movement Scale

Keywords

  • Adverse drug reaction
  • Antipsychotic medication
  • Candidate gene association
  • Genetic
  • Schizophrenia
  • Tardive dyskinesia

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. / Tsai, Huei Ting; Caroff, Stanley N.; Miller, Del D.; McEvoy, Joseph Patrick; Lieberman, Jeffrey A.; North, Kari E.; Scott Stroup, T.; Sullivan, Patrick F.

In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 153, No. 1, 01.01.2010, p. 336-340.

Research output: Contribution to journalArticle

Tsai, HT, Caroff, SN, Miller, DD, McEvoy, JP, Lieberman, JA, North, KE, Scott Stroup, T & Sullivan, PF 2010, 'A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial', American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, vol. 153, no. 1, pp. 336-340. https://doi.org/10.1002/ajmg.b.30981
Tsai, Huei Ting ; Caroff, Stanley N. ; Miller, Del D. ; McEvoy, Joseph Patrick ; Lieberman, Jeffrey A. ; North, Kari E. ; Scott Stroup, T. ; Sullivan, Patrick F. / A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2010 ; Vol. 153, No. 1. pp. 336-340.
@article{76d7c894a367488393711449d7e6aa8f,
title = "A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial",
abstract = "Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2{\%}). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.",
keywords = "Adverse drug reaction, Antipsychotic medication, Candidate gene association, Genetic, Schizophrenia, Tardive dyskinesia",
author = "Tsai, {Huei Ting} and Caroff, {Stanley N.} and Miller, {Del D.} and McEvoy, {Joseph Patrick} and Lieberman, {Jeffrey A.} and North, {Kari E.} and {Scott Stroup}, T. and Sullivan, {Patrick F.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1002/ajmg.b.30981",
language = "English (US)",
volume = "153",
pages = "336--340",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial

AU - Tsai, Huei Ting

AU - Caroff, Stanley N.

AU - Miller, Del D.

AU - McEvoy, Joseph Patrick

AU - Lieberman, Jeffrey A.

AU - North, Kari E.

AU - Scott Stroup, T.

AU - Sullivan, Patrick F.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.

AB - Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, andGABApathways) and composite genotypes for 10 drug -metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature.

KW - Adverse drug reaction

KW - Antipsychotic medication

KW - Candidate gene association

KW - Genetic

KW - Schizophrenia

KW - Tardive dyskinesia

UR - http://www.scopus.com/inward/record.url?scp=73949086059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949086059&partnerID=8YFLogxK

U2 - 10.1002/ajmg.b.30981

DO - 10.1002/ajmg.b.30981

M3 - Article

VL - 153

SP - 336

EP - 340

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 1

ER -